Immuneering appoints Grant C. Bogle to board as Class III Director
The Cambridge biotech added Bogle to its board effective November 9, 2026, with no committee assignment yet disclosed.
SEC filing
2 stories
The Cambridge biotech added Bogle to its board effective November 9, 2026, with no committee assignment yet disclosed.
SEC filing
The company said it has FDA alignment on a registrational path for AATD drug WVE-006 and reported $431.0 million in cash as of September 30, 2026.
SEC filing (7)